TSE:4568Pharmaceuticals
Why Daiichi Sankyo Company (TSE:4568) Is Up 6.8% After ENHERTU Priority Review And Patent Win
In March 2026, Daiichi Sankyo reported multiple developments, including U.S. FDA Priority Review for a supplemental Biologics License Application for ENHERTU in HER2 positive breast cancer, two new research collaborations in advanced antibody and ADC discovery with Voro Therapeutics and Leveragen, and the conclusion of a long-running U.S. patent dispute with Seagen in its favor.
These updates highlight how Daiichi Sankyo is both expanding the clinical footprint of ENHERTU and reinforcing its...